Pell Bio-Med Technology Co., Ltd. (TPE:6949)
Taiwan · Delayed Price · Currency is TWD 562.00
-8.00 (-1.40%)
Apr 2, 2026, 1:30 PM CST
Pell Bio-Med Technology Revenue
In the year 2025, Pell Bio-Med Technology had annual revenue of 31.42M TWD with 60.07% growth. Pell Bio-Med Technology had revenue of 6.07M in the quarter ending December 31, 2025, with 30.85% growth.
Revenue
31.42M
Revenue Growth
+60.07%
P/S Ratio
1,157.43
Revenue / Employee
n/a
Employees
n/a
Market Cap
36.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.42M | 11.79M | 60.07% |
| Dec 31, 2024 | 19.63M | 1.60M | 8.86% |
| Dec 31, 2023 | 18.03M | 876.00K | 5.11% |
| Dec 31, 2022 | 17.16M | 3.18M | 22.75% |
| Dec 31, 2021 | 13.98M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.03B |
| Ever Supreme Bio Technology | 1.02B |
| EirGenix | 1.01B |
| Medigen Vaccine Biologics | 613.17M |
| TaiMed Biologics | 611.35M |
| Tanvex BioPharma | 400.97M |
| Oneness Biotech | 129.12M |
| Polaris Group | 40.60M |